Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

NCT04606602 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemias
Dyslipidemias
Elevated Lp(a)

Interventions

DRUG: SLN360
DRUG: Placebo

Sponsor

Silence Therapeutics plc

Collaborators

[object Object]